Ganoderic Acid a Promotes Functional Recovery After Traumatic Brain Injury By Protecting Blood-brain Barrier Integrity and Modulating Microglial Polarization.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model and in vitro cell study with no human clinical data.
PubMed 41973273 · doi:10.1007/s11481-026-10289-8
What was done
Researchers investigated the neuroprotective effects of Ganoderic acid A (GAA), a triterpenoid from *Ganoderma lucidum*, in a traumatic brain injury (TBI) mouse model and in H₂O₂-induced BV-2 microglial cells. Outcomes evaluated from the abstract include blood-brain barrier (BBB) integrity markers (Evans blue extravasation, brain edema, MMP-9, and tight junction proteins ZO-1, Occludin, Claudin-5), glial activation and microglial polarization (M1 vs. M2 markers and cytokines), synaptic plasticity indices (dendritic spine density, PSD95, SYN, neuronal loss), in vitro oxidative stress and inflammation, and behavioral performance (anxiety-like behavior and spatial memory).
What was found
The abstract reports directional outcomes without providing numerical values, sample sizes, or statistical confidence intervals. GAA treatment preserved BBB integrity, decreased MMP-9 expression, and up-regulated ZO-1, Occludin, and Claudin-5 while reducing Evans blue extravasation and brain edema. GAA attenuated microglial and astrocytic activation, shifted microglia from M1 to M2 phenotypes, reduced BV-2 oxidative stress and inflammation, up-regulated PSD95 and SYN, increased dendritic spine density, reduced neuronal loss, and improved spatial memory deficits and anxiety-like behavior in TBI mice.
Why it matters
Secondary injury mechanisms in TBI lack effective clinical therapies. These findings highlight GAA as a multi-target compound that concurrently addresses vascular barrier breakdown, neuroinflammation, and synaptic disruption in experimental models.
Limits
The study is restricted to rodent and cell-line models that do not replicate human clinical TBI complexity. The abstract provides no quantitative data, effect sizes, dosing regimens, timing of administration, or sample size.
Cited by
- supports M1-activated microglia destroy synapses, generate neuroinflammation, impair neuronal function, and increase the permeability of the blood-brain barrier.